Dr. Rajeev Singh Raghuvanshi is India’s foremost pharmaceutical regulatory leader, currently serving as the Drugs Controller General of India (DCGI) and heading the Central Drugs Standard Control Organization (CDSCO) under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India. Since assuming office in 2023, he has been at the helm of India’s apex drug regulatory authority, overseeing the approval, regulation, safety, and quality standards of pharmaceuticals, vaccines, medical devices, and clinical trials across one of the world’s largest healthcare markets.

A distinguished scientist-administrator with deep expertise in pharmacology, regulatory science, and pharmaceutical innovation, Dr. Raghuvanshi brings decades of experience spanning public institutions, research organizations, and the private pharmaceutical sector. Prior to becoming DCGI, he served as Secretary-cum-Scientific Director of the Indian Pharmacopoeia Commission (IPC), where he played a crucial role in strengthening India’s drug standards, pharmacovigilance systems, and scientific frameworks for medicine quality assurance. His career has also included leadership roles with major pharmaceutical and research organizations, where he contributed to drug development, regulatory strategy, and scientific advancement.

As DCGI, his core mission is centered on ensuring safe, effective, and globally compliant healthcare products for India while modernizing the regulatory ecosystem to keep pace with rapid medical innovation. Under his leadership, CDSCO has emphasized stronger compliance frameworks, upgraded manufacturing standards, accelerated review systems for advanced therapies, and expanded regulatory preparedness for complex innovations such as cell and gene therapies. He has also championed broader stakeholder inclusion by integrating non-government and international experts into scientific review processes, reinforcing India’s global regulatory credibility.

Dr. Raghuvanshi’s leadership is particularly significant in an era where India is a global pharmaceutical manufacturing powerhouse. His work focuses not only on public health protection but also on balancing innovation, patient safety, and industry growth—ensuring India remains competitive in global healthcare while maintaining rigorous standards. Through strategic oversight, scientific rigor, and policy modernization, Dr. Rajeev Singh Raghuvanshi continues to shape the future of India’s healthcare regulatory framework and strengthen the nation’s position in the global life sciences ecosystem.